Funding News Edition: January 08, 2020 See more articles in this edition
NIAID aims to support research projects that develop preventive nucleic acid-based vaccine platforms to protect against seasonal or pandemic influenza. Ideally, these platforms will allow for flexible, nimble, large-scale production of vaccines that can also meet the rapid manufacturing requirements needed during an influenza pandemic.
As described in Notice of Special Interest (NOSI): Development of Nucleic Acid-Based Vaccines Against Seasonal and/or Pandemic Influenza, we encourage applicants to propose such research through the following funding opportunity announcements (FOAs):
- Advancing Research Needed To Develop a Universal Influenza Vaccine (R01, Clinical Trial Not Allowed)
- Advancing Research Needed To Develop a Universal Influenza Vaccine (R21, Clinical Trial Not Allowed)
- PHS 2019-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42], Clinical Trial Not Allowed)
- PHS 2019-02 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44], Clinical Trial Not Allowed)
Several candidate nucleic acid-based vaccines are already entering clinical trials, though NIAID remains interested in further preclinical development. NIAID will also consider nucleic acid-based vaccines that encode prophylactic monoclonal antibodies.
Should you apply in response to this NOSI, you must include “NOT-AI-20-017” (without quotation marks) in the Agency Routing Identifier field (box 4B) of the SF 424 R&R form. Otherwise, follow the due dates and other administrative requirements of the FOA through which you submit your application.
The first available due dates through this NOSI’s linked FOAs are February 5 for R01 applications, March 16 for R21 applications, and April 6 for small business applications. The NOSI will remain open through September 8, 2021.
If you have any questions, reach out to Dr. Jennifer Gordon, NIAID’s scientific contact for the NOSI.